Key Takeaways from Exact Sciences Stock's Earnings

Exact Sciences is one of the most heavily shorted stocks in the health-care sector. Did the company give short-sellers any compelling reasons to cover in yesterday's earnings report?

Jul 23, 2014 at 2:00PM

Short interest is an important metric that could determine, at least in the near term, the general direction of a company's share price. Exact Sciences (NASDAQ:EXAS) has been one of the most heavily shorted stocks in the health-care sector this year, despite making significant progress on the clinical and regulatory fronts for its noninvasive "Cologuard" colorectal cancer screening test. Even so, the company's share price has ballooned upward by over 40% to date in 2014.

Exact's strong performance in the face of high short interest is directly tied to Cologuard's march toward approval. Specifically, an advisory committee for the Food and Drug Administration voted unanimously in March in support of the product's approval.

With peak sales estimated at between $1 billion and $2 billion annually for this novel molecular diagnostic, shorts would appear to have ample reasons to hit the exits prior to final approval and commercialization. The latest short numbers demonstrate a small dip in short interest in recent weeks, as shown by the chart below. With this in mind, let's look at the key takeaways from Exact's second-quarter earnings release yesterday and consider whether shorts should continue their exodus. 

EXAS Chart

EXAS data by YCharts.

Exact Sciences is gearing up for Cologuard's launch
Although Exact's second-quarter numbers aren't pretty from a fundamental perspective, they tell the story of a company on the cusp of morphing into a commercial operation. For the quarter, the company's net loss per share grew to $0.24 from $0.19 for the same period a year ago. Management noted on the earnings conference call that a big chunk of this increase was due to the hiring of a 120-member sales team that averages over 10 years of experience in the field.

As a result, Exact's run-rate rose to approximately $6.5 million per month for the quarter, compared to roughly $3.8 million a year ago. Going forward, the company expects its sales force to grow up to 150 by year-end and the run rate to potentially exceed $7.5 million a month. With $234.8 million remaining in cash and cash equivalents, the company should have a cash runway of two-plus years, excluding revenue from Cologuard. Put simply, Exact should have more than enough cash to successfully launch this product, assuming final approval is forthcoming.

Regulatory and payer updates
Management also noted on the call the final FDA approval looks to be about 30 to 45 days away. The FDA inspection wrapped up without finding deficiencies in Cologuard. As a result, the last major hurdle appears to be the details of the required post-marketing studies.  

On the call, we also learned that Exact has formally discussed a proposed reimbursement scheme for Cologuard with the Centers for Medicare & Medicaid Services, with the proposed total price coming in at $502. Management expects a decision from CMS in the fourth quarter of this year, but private payers won't make their decision until after final FDA approval. 

The major effect of these payer issues will be that revenue from Cologuard, assuming approval, will probably be minimal this year. Essentially, the vast majority of the initial group of patients will have to pay out of pocket. With reimbursement issues seemingly set to be resolved late this year, we should get a better feel for Cologuard's real commercial potential in the first quarter of 2015. 

Foolish wrap-up
Based on what we know now, investors and shorts alike should be asking themselves if Exact looks like a long-term winner. My view is that Exact will probably do fairly well with Cologuard in the near term, but its long-term prospects are less favorable.

The main problem is that Exact will be highly dependent upon Cologuard for top-line growth and the diagnostic field is known for its extreme level of competition. If Cologuard begins to take off, I would imagine diagnostic makers such as Meridian Biosciences and Thermo Fisher Scientific will get in on the act. Indeed, these two companies are already battling over a number of diagnostic tests, especially in the C. difficile product arena. 

Perhaps seeing the writing on the proverbial wall, Exact's management noted that it is actively developing additional GI diagnostic tools based on this same technology. That being said, I don't believe Cologuard will end up garnering the lofty sales numbers projected initially, because this area is simply too prone to attracting copycats, many of which have far more resources than Exact.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


George Budwell has no position in any stocks mentioned. The Motley Fool recommends Thermo Fisher Scientific. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information